Pamvatamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, pamvatamig simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. The binding results in antibody-dependent cellular cytotoxicity (ADCC), thereby inhibiting tumor cell proliferation and survival. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.

**Synonyms:** - Anti-EGFR/c-Met Bispecific Antibody MCLA-129 - Bispecific EGFR-c-Met Antibody MCLA-129 - MCLA 129 - MCLA-129 - MCLA129 - PAMVATAMIG